Depressive Disorder Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of controlled-release (CR) formulation of paroxetine orally administered to patients with major depressive disorder (MDD) at a dose level in the range of 25 - 50 mg/day (initial dose level, 12.5 or 25 mg/day) once daily after evening meal for 8 weeks based on the decrease in HAM-D (Hamilton Depression Rating Scale) total score, to evaluate the safety based on adverse events, laboratory data and vital signs, and to describe the efficacy and safety of immediate release (IR) formulation of paroxetine.
Status | Completed |
Enrollment | 416 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: <at the start of placebo run-in phase> Only the patients who meet all of the following conditions at Week -1 (at the start of placebo run-in phase) will be enrolled in this study. The hospitalization status will be no object. and Gender: No object. - Target disease: Patients diagnosed as having one of the following depressive disorders based on DSM-IV-TR classification in conjunction with M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) and showing currently a symptom of depression or depressed sate - Major depressive disorder, single episode (296.2) (excluding those accompanied by comorbid psychiatric disorders) - Major depressive disorder, recurrent (296.3) (excluding those accompanied by comorbid psychiatric disorders) - Age: >= 20 years (at the time of obtaining consent) - Consent: Patients from whom written consent to participate in this study can be obtained - Gender: - Female patients of childbearing potential can be enrolled. But, such patients who can be enrolled are limited to only those who are negative in the pregnancy test performed at the start of the placebo run-in phase and who agree to receive a pregnancy test at the time point defined in the study period and surely perform any of the contraceptive methods. - Male subjects must abstain from (or use a condom during) sexual intercourse with a pregnant or lactating female. Male subjects must abstain from or use a condom plus spermicidal agent (foam/gel/film/cream/suppository) during sexual intercourse with a female of child-bearing potential. - Patients whose HAM-D (17 items) total score is >= 20 points - Patients whose duration of current episode at least 12 weeks but no longer than 24 months - Patients whose score of "depressed mood" (HAM-D Item 1) is >= 2 points - QTc<450 millisecond (msec) or <480 msec for patients with Bundle Branch Block - values based on either single ECG values or triplicate ECG averaged QTc values obtained over a brief recording period. For the purposes of these criteria, QTc B (Bazett's correction) is defined as (QT interval [msec]) /(square root of RR interval [seconds]) <at the start of treatment phase> Only the patients who meet all of the following conditions at Week -1 (at the start of the placebo run-in phase) and Week 0 (at the start of treatment phase) can be shifted to the treatment phase. - Patients whose HAM-D (17 items) total score is >=20 points - Patients whose score of "depressed mood" (HAM-D Item 1) is >=2 points Exclusion Criteria: <at the start of placebo run-in phase> The patients who are meeting any of the following conditions at Week -1 (at the start of placebo run-in phase) must not be enrolled in this study. - Patients whose primary diagnosis is a disorder classified to Axis I other than major depressive disorder in DSM-IV-TR classification (dysthymic disorder, eating disorder, specific phobia (monophobia), posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder, etc.) - Patients with a current DSM-IV-TR Axis II diagnosis that suggested non-responsiveness to pharmacotherapy or non- compliance with the protocol (e.g., antisocial or borderline personality disorder) - Patients with a history or complication of another (non-MDD) mental disorder (schizophrenia, etc.) - Patients with a history or complication of manic episodes - Patients diagnosed as having an attentional deficit disorder or hyperactivity disorder - Patients diagnosed as having a pervasive development disorder or mental retardation - Patients diagnosed as abusing or dependent on alcohol or drug within one year before the Week -1 visit - Patients who have undergone electroconvulsive therapy within one year before the Week -1 visit for the treatment of the current episode - Patients who have a history of treatment with depot neuroleptics - Patients with a history of serotonin syndrome or neuroleptic malignant syndrome - Patients with a >= 3-point score of "suicide" (HAM-D Item 3) or patients whose Columbia Suicide Severity Rating Scale (C-SSRS) assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the investigator (subinvestigator), are at significant risk for harming self or others. - Patients with a history of suicide attempt, self-injurious action (excluding action with no intention of suicide) or overdosage (excluding apparently accidental overdosage) - Patients who have taken another investigational product or a drug used in a post-marketing clinical study within 12 weeks before the Week -1 visit - Patients with glaucoma - Patients with a convulsive disorder such as epilepsy or a history of it - Patients using a drug increasing an onset risk of bleeding, patients with a bleeding tendency or bleeding diathesis - Patients complicated with severe renal or hepatic dysfunction - Patients complicated with serious organic brain disorder - Patients with a history or complication of cancer or malignant tumor - Patients complicated by chronic hepatitis B or C being positive in test of hepatitis B surface antigen (HbsAg) or hepatitis C antibody - Pregnant, lactating or possibly pregnant female patients, and female patients wishing to be pregnant during the study period - Patients who have previously been unresponsive to paroxetine therapy (e.g. >4wks unresponsive to paroxetine for depression). - Patients with a history of having discontinued treatment due to an adverse event caused by paroxetine - Patients with a history of hypersensitivity to paroxetine. - Patients judged ineligible to participate in this study by the investigator or subinvestigator Exclusion criteria < at the start of treatment phase> The patients who are meeting any of the following conditions at Week 0 (at the start of treatment phase) must not be allowed to the treatment phase. - Patients with a 3 or more-point score of "suicide" (HAM-D Item 3) or with a strong suicidal tendency by C-SSRS and investigator clinical judgement. - Patients whose HAM-D (17 items) total score at the Week 0 visit has changed ±25 %, or exceeding the range of ±25 % of the score at the Week -1 visit - Patients whose Drug 1 (run-in placebo) compliance rate in the period from Week -1 to Week 0 has been < 80 % - Patients judged ineligible as the study subjects by the investigator or subinvestigator |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | GSK Investigational Site | Aichi | |
Japan | GSK Investigational Site | Aichi | |
Japan | GSK Investigational Site | Aichi | |
Japan | GSK Investigational Site | Chiba | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Fukuoka | |
Japan | GSK Investigational Site | Gunma | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hokkaido | |
Japan | GSK Investigational Site | Hyogo | |
Japan | GSK Investigational Site | Hyogo | |
Japan | GSK Investigational Site | Hyogo | |
Japan | GSK Investigational Site | Ibaraki | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kanagawa | |
Japan | GSK Investigational Site | Kumamoto | |
Japan | GSK Investigational Site | Kyoto | |
Japan | GSK Investigational Site | Nagano | |
Japan | GSK Investigational Site | Nagano | |
Japan | GSK Investigational Site | Osaka | |
Japan | GSK Investigational Site | Osaka | |
Japan | GSK Investigational Site | Osaka | |
Japan | GSK Investigational Site | Osaka | |
Japan | GSK Investigational Site | Saga | |
Japan | GSK Investigational Site | Saga | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Saitama | |
Japan | GSK Investigational Site | Tochigi | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tokyo | |
Japan | GSK Investigational Site | Tottori | |
Korea, Republic of | GSK Investigational Site | Gwangju | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul | |
Korea, Republic of | GSK Investigational Site | Seoul |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Japan, Korea, Republic of,
Higuchi T, Hong JP, Jung HY, Watanabe Y, Kunitomi T, Kamijima K. Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea. Psychiatry Clin Neurosci. 2011 Dec;65(7):655-63. doi: 10.1111/j.1440-1819.2011.02243.x. Epub 2011 Sep 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 | The HAM-D measures the severity of depressive symptoms in participants with major depressive disorder (MDD). It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Mean change from baseline was calculated as the value at Week 8 minus the Baseline value. | Baseline (Week 0) and Week 8 | No |
Secondary | Mean Change From Baseline in the HAM-D Total Score at Weeks 1, 2, 3, 4, 6, and 8 | The HAM-D measures the severity of depressive symptoms in participants with MDD. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Mean change from baseline was calculated as the value at each time point minus the Baseline value. | Baseline (Week 0); Weeks 1, 2, 3, 4, 6, and 8 | No |
Secondary | Percentage of HAM-D Responders at Weeks 4 and 8 | The HAM-D measures the severity of depressive symptoms in participants with MDD. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is a sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Responders are defined as participants with a 50 percent or greater reduction from baseline in the HAM-D total score. | Weeks 4 and 8 | No |
Secondary | Percentage of HAM-D Remitters at Weeks 4 and 8 | The HAM-D measures the severity of depressive symptoms in participants with MDD. It is a checklist of 17 items that are ranked on a scale of 0-4 or 0-2. The range for the total score (which is the sum of the scores of all 17 items) is 0-52; a higher score indicates greater severity of symptoms. Remitters are defined as participants with a HAM-D total score of 7 or less. | Weeks 4 and 8 | No |
Secondary | Mean Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-SI) Scores at Weeks 1, 2, 3, 4, 6, and 8 | The 7-point CGI-SI scale assesses the clinician's impression of the participant's current illness state. Scores on the CGI-SI range from 1 = not ill at all to 7 = among the most extremely ill. Mean change from baseline was calculated as the value at each time point minus the baseline value. | Baseline (Week 0); Weeks 1, 2, 3, 4, 6, and 8 | No |
Secondary | Percentage of Responders Based on the Clinical Global Impression-Global Improvement (CGI-GI) Scores at Weeks 4 and 8 | The 7-point CGI-GI assesses the participant's improvement or worsening from baseline. Scores on the CGI-GI range from 1 = very much improved to 7 = very much worse. Responders are defined as participants with a score of 1 or 2 = much improved. | Weeks 4 and 8 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01316926 -
Paxil CR Bioequivalence Study Brazil
|
Phase 1 | |
Recruiting |
NCT06187454 -
Transcranial Direct Current Stimulation for Depression
|
N/A | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05768126 -
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
|
Phase 4 | |
Completed |
NCT03219879 -
Telephone-administered Relapse Prevention for Depression
|
N/A | |
Recruiting |
NCT06038721 -
Unified Protocol: Community Connections
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT00069459 -
Seasonal Affective Depression (SAD) Study
|
Phase 1 | |
Recruiting |
NCT05503966 -
Combining Antidepressants and Attention Bias Modification in Depression
|
N/A | |
Recruiting |
NCT03001245 -
Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents
|
N/A | |
Completed |
NCT02939560 -
TMS for Adults With Autism and Depression
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT02542891 -
European Comparative Effectiveness Research on Internet-based Depression Treatment
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Withdrawn |
NCT02238730 -
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
|
N/A | |
Completed |
NCT01597661 -
Bupropion & Cardio Birth Defect (Slone)
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01093053 -
Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations
|
N/A |